Acumen Pharmaceuticals, Inc. (ABOS) Stock Analysis
Over the past 5 years, Acumen Pharmaceuticals (ABOS) earnings per share (EPS) declined 133.8% a year, revenue declined 20.0% a year and free cash flow declined 290.4% a year, with a 10-year average return on invested capital (ROIC) of -54.3%. ABOS stock trades at $2.31.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate.
Exhibit A Growth Dossier
| Metric | 10yr | 5yr | 1yr | Grade |
|---|---|---|---|---|
| Book Value/Share GrowthBV/S | — | 55.8% | -68.9% | F |
| EPS GrowthEPS Improving, but still negative | — | -133.8% | 30.2% | F |
| Revenue GrowthRevenue | — | -20.0% | — | F |
| Cash Flow GrowthCash Flow Improving, but still negative | — | -290.4% | 28.9% | F |
| ROICROIC | -54.3% | -45.8% | -121.7% | F |
Exhibit B Valuation Ledger
- Current EPS
- -$1.55
- Historical Avg P/E
- —
- Future P/E (used for sticker price)
- Projected EPS (10yr)
- Sticker Price (10yr)
- Price for 15% Annual Return
- Expected Annual Return
No card required. $5/month after the trial if you keep going.
Not investment advice — a structured read of historical fundamentals, not a forecast or recommendation. Always do your own research.
Exhibit C Raw Data (last 10 years)
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Book Value / ShareBV/S | -$0.40 | -$0.65 | $5.88 | $4.65 | $5.49 | $3.03 | $1.16 | $0.48 | |
| Basic EPSEPS | -$0.20 | -$0.26 | -$2.63 | -$1.06 | -$1.08 | -$1.71 | -$2.00 | -$1.55 | |
| RevenueRevenue | $1,697,000 | $1,436,000 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Free Cash FlowCash Flow | $-6,818,000 | $-7,450,000 | $-18,001,000 | $-35,314,000 | $-43,085,000 | $-86,231,000 | $-115,626,000 | $-87,952,000 | |
| ROIC (%)ROIC | -130.5% | -20.8% | -8.7% | -24.0% | -20.5% | -53.9% | -121.7% | — |
The exact underlying data used to compute the growth rates and grades above. The highlighted TTM column is the trailing twelve months through the most recently reported quarter.
Ticker INVESTigator Price Target
Analyst Data
Price Target
Where the stock trades today vs. the range of 12-month price targets from covering analysts.
1 price target — not a consensus range · 8 firms rate it — 8 buy · No target published in the last 12 months
ABOS Stock FAQ
What is ABOS's stock price target?
There is one analyst price target for ABOS: $7.00, +203.7% from the current price of $2.31. No analyst has published a new target in the last 12 months, so treat it with caution.
Do analysts rate ABOS a buy?
Most rate it a buy. Of 8 firms covering Acumen Pharmaceuticals, the ratings are 8 buy or strong buy, 0 hold and 0 sell or strong sell.
How fast is Acumen Pharmaceuticals growing?
Annual growth rates for ABOS. EPS: -133.8% over 5 years, 30.2% over 1 year. Revenue: -20.0% over 5 years. Free cash flow: -290.4% over 5 years, 28.9% over 1 year. Book value per share: 55.8% over 5 years, -68.9% over 1 year.
What is ABOS's ROIC?
Acumen Pharmaceuticals' return on invested capital (ROIC) was -121.7% in fiscal 2025. Its 10-year average ROIC is -54.3%. ROIC above 10% is generally a sign of a business with a durable competitive advantage.
What is ABOS's P/E ratio?
ABOS has no meaningful P/E ratio right now because its earnings are negative. Trailing earnings per share are -$1.55.
What is Acumen Pharmaceuticals' market cap and stock price?
ABOS last traded at $2.31 as of October 28, 2026. Its 52-week range is $1.50 to $3.60. Acumen Pharmaceuticals has a market cap of $166.7M.
Exhibit D Related Coverage
Similar Stocks
Data as of October 28, 2026. Findings are derived from historical fundamentals — not a forecast, not advice. Cross-examine before you invest.
Grades are produced by Ticker INVESTigator's own model from public financial data and are for informational and educational purposes only. They are not investment advice or a recommendation to buy or sell any security. Do your own research.